ストックスクリーナーアプリを入手
12.20
0.33%
-0.075
アフターアワーズ：
12.20
0.005
+0.04%
前日終値:
$12.27
開ける：
$12.07
24時間の取引高:
2.19M
Relative Volume:
0.78
時価総額：
$10.16B
収益：
$3.81B
当期純損益:
$485.75M
株価収益率:
20.76
EPS:
0.5873
ネットキャッシュフロー:
$175.50M
1週間 パフォーマンス:
-0.16%
1か月 パフォーマンス:
+2.95%
6か月 パフォーマンス:
-7.63%
1年 パフォーマンス:
-12.58%
1日の値動き範囲:
$11.99
$12.29
1週間の範囲:
$11.99
$12.55
52週間の値動き範囲:
$11.36
$15.67
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
12.20 | 10.20B | 3.81B | 485.75M | 175.50M | 0.5873 |
TAK
Takeda Pharmaceutical Co Adr
|
18.50 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.20 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.255 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.06 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
532.78 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-23 | ダウングレード | Goldman | Neutral → Sell |
| 2025-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-12-19 | ダウングレード | Nomura | Buy → Neutral |
| 2024-01-11 | ダウングレード | Jefferies | Buy → Underperform |
| 2023-08-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-05-18 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-30 | 開始されました | JP Morgan | Underweight |
| 2022-11-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 再開されました | BofA Securities | Neutral |
| 2021-07-27 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-09-18 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-09-18 | アップグレード | Investec | Sell → Hold |
| 2020-01-28 | ダウングレード | CLSA | Buy → Outperform |
| 2020-01-27 | ダウングレード | CLSA | Buy → Outperform |
| 2020-01-09 | アップグレード | Citigroup | Sell → Buy |
| 2019-11-04 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | アップグレード | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | アップグレード | Macquarie | Neutral → Outperform |
| 2019-06-20 | 開始されました | Deutsche Bank | Hold |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-20 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | アップグレード | CLSA | Outperform → Buy |
| 2019-01-17 | ダウングレード | Citigroup | Neutral → Sell |
| 2017-09-21 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | アップグレード | CLSA | Underperform → Outperform |
| 2017-07-28 | ダウングレード | CLSA | Underperform → Sell |
| 2016-07-27 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2016-07-27 | ダウングレード | Jefferies | Hold → Underperform |
| 2016-02-10 | アップグレード | Credit Agricole | Underperform → Buy |
| 2015-11-10 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Dr Reddys Laboratories Ltd Adr (RDY) 最新ニュース
Dr. Reddy’s Labs ADR wedged in $12.35-$12.77 range: Live levels - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - GlobeNewswire Inc.
Dr. Reddy’s ADR consolidates in Ichimoku cloud: Live levels By Investing.com - Investing.com India
Dr. Reddy's Laboratories stock holds steady as investors digest recent earnings and valuation - AD HOC NEWS
Dr Reddy's Laboratories stock gains attention on QDENGA vaccine deal - AD HOC NEWS
ETFs Investing in Dr. Reddy's Laboratories Ltd. Sponsored ADR Stocks - TradingView
Dr. Reddy’s Labs ADR stuck in ₹11.90-₹12.35 range: Live levels - Investing.com India
Semaglutide Drug Market Analysis Report: $37,151.93 Million Scale in 2026, 9.93% Growth Rate Trend｜QYResearch - note
Dr. Reddy’s Issues New ESOP Shares After ADR Option Exercise - TipRanks
Dr. Reddy’s (NYSE: RDY) adds 375 shares via employee options - Stock Titan
Dr. Reddy’s ADR tests $11.70 support after bearish close: Live levels - Investing.com India
Dr. Reddy’s ADR tests key support 4th time: Live levels By Investing.com - Investing.com India
Elanco Animal Health (ELAN) Peer Comparison – Compare with Others - Value Research
GLP-1 sales in Canada on pace to set a new record this year - theglobeandmail.com
Dr. Reddy’s Labs ADR trapped in no-trade zone: Live levels - Investing.com India
Dr. Reddy’s ADR tests ₹12.00 support: Live levels By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Dr. Reddy’s ADR bear flag 80% complete: Live levels By Investing.com - Investing.com India
Dr. Reddy’s Labs ADR tests 50 SMA with doji: Live levels - Investing.com India
Dr. Reddy's Laboratories (RDY) Securities Investigation NoticeLevi & Korsinsky - Sahm
HDFC Bank Limited (HDB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Neutral Dr Reddy's Labs Ltd For Target Rs.1,125 Motilal Oswal Financial services Ltd - Investment Guru India
Dr. Reddy’s Labs ADR earnings missed by $0.03, revenue fell short of estimates By Investing.com - Investing.com South Africa
Dr Reddy's share price: Why this stock plunged 9% today; more downside ahead? - Business Today
Dr. Reddy's Labs shares fall 4% after weak Q1 results; Profit slumps 69%, margins shrink - Business Upturn
Dr Reddy's Labs share price to track 9% ADR fall; targets by CLSA, Nomura, Goldman Sachs, Citi, others - Business Today
Q1 Results LIVE Updates: Infosys, Cipla, IndiGo report today; Dr Reddy's ADR tanks 10% - CNBC TV18
Dr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings miss - CNBC TV18
Dr. Reddy’s Labs ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com India
Dr. Reddy's Earnings: Reduced Lenalidomide Sales and Semaglutide Challenge Mark a Weak Start to Year - Morningstar
Dr. Reddy's Starts Year on Weak Ground as Lenalidomide and Semaglutide Impacts Weigh on Results - Morningstar
Earnings call transcript: Dr. Reddy’s misses Q1 2026 EPS forecast as stock falls 8% - Investing.com
Dr Reddy’s ADR falls 5% as profit drops sharplyCheck details - CNBC TV18
Dr Reddy’s ADR falls over 5% after Q1 results miss analyst estimates despite already muted expectations - Business Upturn
ASML Holding N.V. Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies - GlobeNewswire Inc.
Price to earnings forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr Reddy's shares: Semaglutide woes to trigger EPS cuts; Should you buy, sell or hold? - Business Today
Korea’s SK Hynix makes history in US – raises $26.5 billion in largest foreign debut - financialexpress.com
SK Hynix plans to price its US listing at $149 - financialexpress.com
Dr Reddy's Shares Slide Over 6% After Semaglutide Batch Quality Concern - NDTV Profit
Dr. Reddy's Labs ADR highlights its global generics footprint as investors track U.S. healthcare dem - ad-hoc-news.de
Dr. Reddy's Labs ADR highlights global generics reach. Investors look at U.S. listing context - AD HOC NEWS
RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call - sahmcapital.com
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy’s Laboratories files FY26 annual report with US SEC - scanx.trade
Dr Reddys Laboratories Ltd Adr (RDY) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
0.59%
大文字化:
|
ボリューム (24 時間):